Catalyst

Slingshot members are tracking this event:

REGENXBIO and Biogen Enter Exclusive License Agreement for the Development of Gene Therapy Treatments for Rare Genetic Vision Disorders

Source Link:
http://ir.regenxbio.com/phoenix.zhtml?c=254175&p=irol-newsArticle&cat=news&id=2168467

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
RGNX Community voting in process
BIIB Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
May 16, 2016
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords License Agreement, Rare Genetic Vision Disorders, Gene Therapy Treatments
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.